6-Aminohexyl-D-glucopyranosid | 150447-15-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: 6-Aminohexyl-D-glucopyranosid
• 英文别名: (3R,4S,5S,6R)-2-(6-aminohexoxy)-6-(hydroxymethyl)oxane-3,4,5-triol
• CAS: 150447-15-7
• 化学式: C₁₂H₂₅NO₆
• 分子量: 279.334
• InChiKey: GWNKFVGAEZHVTM-OZRWLHRGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  19
• 可旋转键数：
  8
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  125
• 氢给体数：
  5
• 氢受体数：
  7

文献信息

• Sugar chain-containing water-soluble polymer compound
  申请人：Nishiguchi Susumu

  公开号：US20060287457A1

  公开（公告）日：2006-12-21

  A polymer compound having a monosaccharide or an oligosaccharide residue, or an amino acid or peptide residue bound to a monosaccharide or an oligosaccharide residue bound to a side chain of a water-soluble polymer through a linker containing a selectively cleavable bond, the water-soluble polymer containing 20 to 80 mol % of (meth)acrylic acid residue.

  这是一种聚合物化合物，它含有单糖或寡糖残基，或者氨基酸或肽残基与单糖或寡糖残基通过一个含有可选择断裂键的连接剂结合到水溶性聚合物的侧链上，其中水溶性聚合物含有20-80摩尔％的（甲基）丙烯酸残基。
• Methods and Compositions For Treating Diseases and Disorders Associated With Siglec-8 Expressing Cells
  申请人：Bochner Bruce S.

  公开号：US20080139485A1

  公开（公告）日：2008-06-12

  The invention provides therapeutic methods and compositions for the prevention and treatment of Siglec-8 associated diseases and disorders such as asthma and allergic reactions. In particular, the invention provides methods and compositions for the prevention and treatment of diseases and disorders associated with Siglec-8 expressing cells in humans, as well as other animals, through the administration of one or more novel, carbohydrate-based compounds.
• METHODS AND COMPOSITIONS FOR TREATING DISEASES AND DISORDERS ASSOCIATED WITH SIGLEC-8
  申请人：Bochner Bruce Scott

  公开号：US20110046078A1

  公开（公告）日：2011-02-24

  The invention provides therapeutic methods and compositions for the prevention and treatment of Siglec-8 associated diseases and disorders such as asthma and allergic reactions. In particular, the invention provides methods and compositions for the prevention and treatment of diseases and disorders associated with Siglec-8 expressing cells in humans, as well as other animals, through the administration of one or more novel, carbohydrate-based compounds.
• US7700701B2
  申请人：——

  公开号：US7700701B2

  公开（公告）日：2010-04-20
• US7745421B2
  申请人：——

  公开号：US7745421B2

  公开（公告）日：2010-06-29